GB2137206A - Androstane 17-carbothioc acid derivatives - Google Patents

Androstane 17-carbothioc acid derivatives Download PDF

Info

Publication number
GB2137206A
GB2137206A GB08325400A GB8325400A GB2137206A GB 2137206 A GB2137206 A GB 2137206A GB 08325400 A GB08325400 A GB 08325400A GB 8325400 A GB8325400 A GB 8325400A GB 2137206 A GB2137206 A GB 2137206A
Authority
GB
United Kingdom
Prior art keywords
group
alpha
compounds
formula
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB08325400A
Other versions
GB2137206B (en
GB8325400D0 (en
Inventor
Gordon Hanley Phillipps
Brian Macdonald Bain
Christopher Williamson
Ian Phillip Steeples
Stuart Bruce Laing
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GB08325400A priority Critical patent/GB2137206B/en
Publication of GB8325400D0 publication Critical patent/GB8325400D0/en
Publication of GB2137206A publication Critical patent/GB2137206A/en
Application granted granted Critical
Publication of GB2137206B publication Critical patent/GB2137206B/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005Oxygen-containing hetero ring
    • C07J71/001Oxiranes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J3/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0038Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 with an androstane skeleton, including 18- or 19-substituted derivatives, 18-nor derivatives and also derivatives where position 17-beta is substituted by a carbon atom not directly bonded to a further carbon atom and not being part of an amide group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005Oxygen-containing hetero ring
    • C07J71/001Oxiranes
    • C07J71/0015Oxiranes at position 9(11)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005Oxygen-containing hetero ring
    • C07J71/0026Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031Oxygen-containing hetero ring cyclic ketals at positions 16, 17

Abstract

Compounds of the general formula (II> <IMAGE> [wherein R<a> is a group-COOCSNR<A>R<B> (where R<A> and R<B> are alkyl groups or R<A> and R<B> together complete a 5-8 membered ring which may contain an additional hetero atom selected from O, N and S and may be substituted by one or two C1-3 alkyl groups) or a group -COSR<1A> (where R<1A> is H or is a group as defined below for R<1> or is the group -(CH2)nY in which n is 1 or 2 and Y is a displaceable substituent) and R<b> is esterified hydroxyl or R<b> and R<c> together represent isopropylidenedioxy; or when R<a> is COSR<1A>, R<b> is optionally hydroxyl; R<c> is H, alpha -Me, beta -Me or CH2; R<d> is alpha or beta -hydroxyl (free or protected), or oxo; R<e> is H, Br, Cl or F; or R<d> and R<e> together represent a carbon-carbon bond or an epoxy group in the beta -configuration; R<f> is H or F and .... represents a single or double bond] and salts of those compounds which have a free carbothioic acid group; with the exclusion of compounds of the formula:- <IMAGE> wherein R<1> is fluoro-, chloro- or bromomethyl or 2'-fluoroethyl, R<2> is COR<6> where R<6> is C1-3 alkyl or OR<2> and R<3> together form 16 alpha ,17 alpha -isopropylidenedioxy; R<3> is H, alpha -Me, beta -Me or CH2; R<4> is H, Cl or F; R<5> is H or F; and .... represents a single or double bond. Compounds of formula II are useful intermediates in the preparation of the compounds of formula I.

Description

SPECIFICATION Steroids of the androstane series Anti-inflammatory steroids are most typically of the corticoid type, i.e. are pregnane derivatives.
Our United Kingdom Patents Nos. 1384372, 1438940 and 1514476 describe esters of certain androxtane 17ss-carboxylic acids having anti-inflammatory activity. European Patent Application No.
79300500.0 (Publication No. 0004741) describes esters of androstane 17p-carbothioic acids also possessing anti-inflammatory activity. We have now discovered that certain androstane compounds containing a haloalkyl carbothioate grouping in the 17ss-position have particularly advantageous antiinflammatory properties as discussed in greater detail below.
The new androstane compounds may be represented by the formula
wherein R' represents a fluoro-, chloro- or bromo-methyl group or a 2'-fluoroethyl group; R2 represents a group COR6 where R6 is a C13 alkyl group or OR2 and R3 together form a 1 6a,1 7a- isopropylidenedioxy group; R3 represents a hydrogen atom, a methyl group (which may be in either the a- or p-configuration) or a methylene group; R4 represents a hydrogen, chlorine or fluorine atom; R5 represents a hydrogen or fluorine atom and symbol ---- represents a single or double bond.
The compounds of formula I hereinbefore defined, processes for their preparation and pharmaceutical compositions containing them are described and claimed in our copending British Patent Application No.8104496 (Serial No.2,088,877).
The new compounds of formula (I) have good anti-inflammatory activity, particularly on topical application, as judged by the McKenzie patch test in man and as measured by the reduction of croton oil induced oedema when the compounds are applied topically to the skin of mice and rats.
Certain of the compounds show good topical anti-inflammatory activity in the croton oil ear test coupled with minimal hypothalamus-pituitary-adrenal-suppressive activity after topical application in the same animal species. These results indicate that such compounds may be of value in the local treatment of inflammation in man and animals with minimal liability to cause undesired systemic side effects.
Compounds of formula (I) which are preferred for their good anti-inflammatory activity include the following categories namely (a) those in which R' is chloro- or fluoromethyl (b) those in which R2 is acetyl or propionyl, preferably propionyl, (c) those in which R4 is fluorine (d) those in which R5 is fluorine (e) the 1,4-dienes, and (f) those 1,4-dienes in which R4 is fluorine and R3 is hydrogen, a- or methyl or methylene.
Compounds of formula (I) which have good anti-inflammatory activity coupled with minimal hypothalamus-pituitary-adrenal-suppressive activity when applied topically include 1 4-dienes in which R' is chloro- or fluoro-methyl, R4 and R5 are fluorine and in particular those in which R3 is methyl.
Especially preferred compounds according to the invention in view of their good topical antiinflammatory activity and favourable ratio of topical anti-inflammatory activity to undesired systemic activity include: S-chloromethyl 9a-fluoro-1 1 -hydrnxy-1 6a-methyl-3-oxo- 1 7a-propionyloxyandrosta-1 4-diene- 17ss-carbothioate; S-chloromethyl 9&alpha;-fluoro-11ss-hydroxy-16-methylene-3-oxo-17&alpha;-propionyloxyandrosta-1,4- diene-17P-carbothioate; S-fluoromethyl 6a,9ez-difluoro- 1 P-hydroxy-l 6a,l 7a-isopropylidenedioxy-3-oxoandrosta- 1,4diene-17ss-carbothioate S-fluoromethyl 6&alpha;,9&alpha;-difluoro-11ss-hydroxy-16&alpha;-methyl-3-oxo-17&alpha;;-propionyloxyandrosta-1,4- diene-17ss-carbothioate; S-chloromethyl 6a,9a-difluoro-1 1 p-hydroxy- 6&alpha;-methyl-3-oxo-17 7a-propionyloxyandrosta- 1,4 diene-1 7-carbothioate. The last compound is especially preferred in view of its particularly favourable ratio and in addition minimal skin atrophy.
The compounds of formula (I) may be prepared by a variety of different processes.
One such process comprises esterifying an androstane compound corresponding to formula (I) but containing either a free 1 -/P-carbothioic acid group (or functionaily equivalent group) or a free 1 7a- hydroxy group (R3 being a hydrogen atom or a methyl or methylene group), any other reactive groups present in the molecule being suitably protected as desired.
For example, a salt of the parent 1 7P-carbothioic acid such as an alkali metal, e.g. lithium, sodium or potassium, salt or an alkylammonium, e.g. triethylammonium or tetrabutylammonium, salt may be reacted with an appropriate alkylating agent, preferably in a polar solvent such as a ketone, e.g. acetone or an amide such as dimethylformamide, dimethylacetamide or hexamethylphosphoramide, conveniently at a temperature of 1 5 to 1000C. The alkyiating agent may comprise an appropriate dihalo compound i.e. one containing a further halogen atom (preferably a bromine or iodine atom) in addition to the halogen atom of the desired R' group.This process is particularly applicable to the preparation of compounds in which R' is a chloromethyl group, the alkylating agent advantageously being bromochloromethane.
Alternatively, the parent 1 6-hydrogen, methyl or methylene-1 7a-hydroxy-1 7-carbothioates corresponding to compounds of formula I may be subjected to esterification of the 1 7a-hydroxyl group.
This may be effected by conventional techniques, e.g. by reacting the parent 1 7a-hydroxy compound with a mixed anhydride of the required carboxylic acid, which may, for example, be generated in situ by reacting the carboxylic acid with an appropriate anhydride such as trifluoroacetic anhydride, preferably in the presence of an acid catalyst, e.g. p-toluenesulphonic acid or sulphosalicylic acid. Alternatively, the mixed anhydride may be generated in situ by reaction of a symmetrical anhydride of the required acid with an appropriate further acid, e.g. trifluoroacetic acid.
The reaction is advantageously effected in an organic solvent medium such as benzene, methylene chloride or an excess of the carboxylic acid employed, the reaction being conveniently effected at a temperature of 20-1 000C.
Alternatively, the 1 7a-hydroxy group may be esterified by reaction of the parent 1 7a-hydroxy compound with the appropriate acid anhydride or acid chloride, if desired, in the presence of non hydroxylic solvents, e.g. chloroform, methylene chloride or benzene, and preferably in the presence of a strong acid catalyst, e.g. perchloric acid, p-toluene sulphonic acid or a strongly acidic cation exchange resin, e.g. Amberlite IR 120, the reaction being conveniently effected at a temperature of 25 to 1000C.
The compounds of formula (I) may also be prepared by reacting a corresponding androstane compound containing a 1 7P-substituent of formula C0S(CH2)nY (wherein Y represents a displaceable substituent and n is 1 or 2) with a compound serving to replace the group Y by a halogen atom.
Thus the compounds of formula (I) may be subjected to a halogen exchange reaction serving to replace the group Y where this is halogen by a different halogen substituent. Thus the bromomethyl, fluoromethyl and fluoroethyl 17P-carbothioate compounds may be prepared from the corresponding iodomethyl or bromoethyl 1 7P-carbothioate compounds using a bromide salt such as lithium bromide in the case of the bromomethyl 17P-carbothioate compounds or an appropriate fluoride e.g. silver monofluoride or silver difluoride in the case of the fluoromethyl or fluoroethyl 1 7-carbothioate compounds.The starting iodomethyl 17P-carbothioate compounds may be prepared from the corresponding chloromethyl 17p-carbothioate compounds using for example, an alkali metal, alkaline earth metal or quaternary ammonium iodide e.g. sodium iodide.
The reaction is advantageously effected in a solvent medium comprising for example acetone, acetonitrile methyl ethyl ketone, dimethylformamide, dimethylacetamide or ethanol.
The foregoing reactions may also be carried out on starting materials having a variety of substituents or groupings which are subsequently converted into those substituents or groupings which are present in the compounds of the invention as defined above.
The 1 1 P-hydroxy compounds of formula (I) may thus be prepared by reduction of a corresponding 11 -oxo compound, e.g. using an alkali metal or alkaline earth metal borohydride, e.g. sodium or calcium borohydride, conveniently in an alcoholic or aqueous alcoholic solvent such as methanol or ethanol.
Such an 1 1-keto compound may be prepared by oxidation of a corresponding 11 a-hydroxysteroid, for example using a chromic acid reagent such as Jones' reagent.
An 1 1 P-hydroxy compound of formula (I) may also be obtained by deprotection of a corresponding compound having a protected hydroxyl group at the 11 /3-position, for example a tri C16 alkylsilyloxy group such as the trimethylsilyloxy group or a perfluoro- or chloro-alkanoyloxy group such as the trifluoroacetoxy group. Removal of the protecting group may be effected by hydrolysis, the trialkylsilyl group, being readily removed by mild acid or basic hydrolysis or particularly conveniently using fluoride e.g. hydrogen fluoride or an ammonium fluoride. The perfluoro- or chloro-alkanoyl protecting group may also be removed by mild acid or basic hydrolysis or alcoholysis, but preferably under acidic conditions when R4 is a chlorine atom. Such a protected hydroxyl group may be introduced, for example, by reacting an 1 1 P-hydroxy steroid with an appropriate reagent such as a trialkylsilyl halide or a perfluoroor chloro-alkanoic anhydride.
Compounds of formula (I) may also be produced by reaction of a corresponding compound having a 9,11-double bond (and no substituent in the 11-position) with reagents serving to introduce the required 9a-halo-1 hydroxy grouping. This may involve initial formation of a bromohydrin by reaction with an N-bromo-amide or -imide such as N-bromosuccinimide, followed by formation of the corresponding 9P,1 3-epoxide by treatment with a base and reaction of the epoxide with hydrogen fluoride or hydrogen chloride to introduce the required fluorohydrin or chlorohydrin grouping respectively. Alternatively, the 9,11-olefin compound may be reacted with an N-chloro-amide or -imide to introduce the required 9-chloro-11,B-hydroxy grouping directly.
The A4-compounds according to the invention can conveniently be prepared by partial reduction of the corresponding A1,4-compound, for example, by hydrogenation using a palladium catalyst, conveniently in a solvent e.g. ethyl acetate or by homogeneous hydrogenation using for example tris(triphenylphosphine) rhodium chloride, conveniently in a solvent such as benzene, or by exchange hydrogenation using for example cyclohexene in the presence of a palladium catalyst in a solvent e.g.
ethanol, preferably under reflux. This reduction may be carried out on a haloalkyl ester where this is sufficiently stable in such a reaction or may be effected at an earlier stage.
The above mentioned compounds containing a free -COSH group in the 17p-position may be prepared for example by aminolysis with rearrangement of a suitable 17P-th iocarbamoyloxycarbonyl androstane. The 17p-thiocarbamoyloxycarbonyl androstane is a mixed an hydride of the corresponding 17ss-carboxylic acid and a thiocarbamic acid and is conveniently prepared by reaction of a salt of the 17p-carboxylic acid 17a-ester or 1 6a,1 7aracetonide with a thiocarbamoyl halide.The thiocarbamoyl group is N,N-disubstituted, and may thus have the formula --COOCSNRARB, where RA and RB, which may be the same or different, are alkyl groups, e.g. C14 alkyl groups or RA and RB together with the nitrogen atom to which they are attached form a 5-8 membered ring which may optionally contain an additional hetero atom selected from oxygen, nitrogen and sulphur and/or which may optionally be substituted by one or two C13 alkyl e.g. methyl groups. Preferably RA and RB are C14 alkyl substituents, the N,N-dimethylthiocarbamoyl group being preferred. The thiocarbamoyl halide is preferably the chloride. The reaction may be accelerated by the addition of an iodide salt e.g. sodium iodide.
The initial androstane 17p-carboxylate salt may be for example, an alkali metal, e.g. sodium or potassium, alkaline earth metal, e.g. calcium, salt or a salt of a tertiary amine, e.g. triethylamine.
Aminolysis with rearrangement may be carried out for example by heating the mixed anhydride to an elevated temperature e.g. in the presence of ammonia, a primary amine or more preferably a secondary amine such as diethylamine or pyrrolidine. In the starting 1 7/3-carboxylic acids, the 16- and 1 7a-positions will conveniently be substituted by the -F3 and -OR2 groupings desired for the final product of formula (I).
17a-Hydroxy androstane compounds in the 16-methylene series which contain the desired 17p- carbothioic acid grouping, as described above, may be prepared from the corresponding 16p-methyl- 16&alpha;,17&alpha;-epoxy 17ss-thiocarboxylic acid, by effecting a rearrangement using a strong acid e.g. a strong carboxylic acid such as trifluoroacetic acid.These 1 6a,1 7a-epoxides may be prepared from the corresponding 17ss-carboxylic acids by treatment with an onium salt of a 2-halo-aza-aromatic compound, followed by treatment of the resulting product with hydrogen sulphide or a salt thereof to give the free 17j-carbothioic acid which may be alkylated as described above, preferably in situ to give the desired 17p-carbothioate group.
1 6a,1 7a-lsopropylidenedioxy compounds of formula (I) may similarly be prepared by treating a corresponding 17ss-carboxylic acid with an onium salt of a 2-halo-aza-aromatic compound followed by treatment of the resulting product with hydrogen sulphide to give the free 17ss-carbothioic acid which may then be esterified as described above.
Onium salts of 2-halo-aza-aromatic compounds are capable of effecting carboxylic activation.
Such reagents include 2-halo-N-alkyl- or 2-halo-N-phenyl-pyridinium or pyrimidinium salts carrying 1 to 2 further substituents selected from phenyl and lower (e.g. C,~4) alkyl groups, such as methyl. The 2halogen atoms can be fluorine, chlorine, bromine or iodine atoms. The salts are preferably sulphonates.
e.g. tosylates; halides e.g. iodides; fluoroborates or perfluoroalkylsulphonates, a convenient salt being 2fluoro-N-methylpyridinium tosylate or 2-chloro-N-methylbenzothiazolium trifluoromethanesulphonate.
The 16&alpha;,17&alpha;-epoxy-16ss-methyl-17ss-carboxylic acid compounds used as starting materials in the above process may be prepared in conventional manner, e.g. as described in British Patent Specification No. 1,517,278.
The starting materials employed in the process described herein for the preparation of compounds of formula (I) are new and constitute a further feature of the invention; they include compounds of the general formula (II)
(wherein Ra represents a thiocarbamoyloxycarbonyl group-COOCSNRARB where RA and RB are as defined above, or a group of the formula-COSR1A, where R1A represents a hydrogen atom or is a group as defined above for R1 or is a group convertible thereto and Rb represents an esterified hydroxyl group or Rb and RC together represent an isopropylidenedioxy group; or where Ra represents a group COSRlA, Rb is optionally a hydroxyl group; Rc represents a hydrogen atom, a methyl group (which may be in either the a- or ,B-configuration) or a methylene group; Rd represents a hydroxy or protected hydroxy group (in either the a- or ,e-configuration) or an oxo group; R3 represents a hydrogen, bromine, chlorine or fluorine atom; or Rd and Re together represent a carbon-carbon bond or an epoxy group in the ss-configuration; Rf represents a hydrogen or a fluorine atom; and the symbol ---- represents a single or double bond and salts of those compounds which have a free carbothioic acid group; with the exclusion of compounds of formula (I) as hereinbefore defined.
Where Rd represents a protected hydroxyl group, this may, for example be a trialkylsilyloxy group or a perfluoro- or perchloro-alkanoyloxy group as defined previously.
The 17&alpha;-hydroxy 17ss-carbothioic acids of formula (II) and salts thereof may be converted into the 17&alpha;-hydroxy 17ss-carbothioates of formula (II) where Ra represents the group COSR1 as defined in formula (I) or into the 17ss-carbothioic acid 17&alpha;-esters of formula (II) by the processes described above for preparing the compounds of formula (I). The esterification of the 1 7a-hydroxy group is preferably effected with the appropriate carboxylic acid chloride in a solvent such as a halogenated hydrocarbon e.g. dichloromethane, and advantageously in the presence of a base such as triethylamine, preferably at a low temperature e.g. OOC.
The 17&alpha;-hydroxy 17ss-carbothioic acids of formula (II) and salts thereof are thus particularly useful intermediates for preparing the androstane 17ss-carbothioates of formula (I); those in which Rc represents a hydrogen atom, an a- or methyl group or a methylene group, Re represents a hydrogen, chlorine or fluorine atom, Rd represents a hydroxy group in the ,B-configuration or an oxo group being preferred.More preferred compounds and salts there of include those compounds in which Rc represents a methyl group in the &alpha;- or ss-configuration or a methylene group; Re represents a fluorine atom, Rd represents a hydroxy group in the /3-configuration or an oxo group and the symbol ---- in the 1,2 position represents a carbon-carbon double bond.
Especially preferred compounds of formula II this include, for example, the following: 9&alpha;-fluoro-11ss, 17&alpha;-dihydroxy-16ss-methyl-3-oxoandrosta-1,4-diene- 17ss-carbothioic acid; 9&alpha;- fluoro-11ss, 17&alpha;-dihydroxy-16ss-methyl-3-oxoandrosta-1,4-diene-17ss-carbothioic acid; 9&alpha;-fluoro- 11ss, 17&alpha;-dihydroxy-16-methylene-3-oxoandrosta-1,4-diene-17ss-carbothioic acid; 6&alpha;,g&alpha;-difluoro- 11ss, 17&alpha;-dihydroxy-16&alpha;-methyl-3-oxoandrosta-1,4-diene-17ss-carbothioic acid and the corresponding 11-ketones and salts thereof.
One advantage of the above intermediates is that they prmit direct haloalkylation to give haloalkyl 17ss-carbothioates when the corresponding thiols R1SH are not available. The salts of these 17&alpha;-hydroxy 17ss-carbothioic acids may, for example be alkali metal, e.g. lithium, sodium or potassium salts; alkaline earth metal, e.g.calcium or magnesium salts; tertiary amine salts, e.g. pyridinium or triethylammonium salts; or quaternary ammonium salts, e.g. tetrabutylammonium salts.
The 17&alpha;-hydroxy 17ss-carbothioic acids may, for example, be prepared by reaction of a reactive derivative of a corresponding 17&alpha;-hydroxy-17ss-carboxylic acid with hydrogen sulphide or a sulphide or hydrosulphide salt thereof. In general, the cation of the sulphide or hydrosulphide salt may be for example an alkali metal salt such as sodium or potassium hydrogen sulphide.The above-mentioned reactive derivatives correspond to compounds of formula (II) where Rb is a hydroxyl group and the group -COR7 is present at the 17ss-position wherein R7 represents a group of the formula
in which X, Y and Z, which may be the same or different, each represent CH or N, one or two of X, Y and Z being N, the heterocyclic ring optionally being substituted on at least one carbon atom by a lower alkyl group (e.g. with 1 to 4 carbon atoms, such as a methyl group) and/or where the heterocyclic ring contains two adjacent carbon atoms, the said ring optionally carrying a benzene ring fused to the said adjacent carbon atoms.
The above-mentioned reactive derivatives corresponding to formula II are preferably prepared by reacting corresponding 17&alpha;-hydroxy-17ss-carboxyfic acids of formula (II) with a symmetric or asymmetric compound of the formula: R7-W-R7 (III) wherein W represents the group CO, CS, SO or SO2 and the groups R7, which may be the same or different, have the above meanings.
The compounds of formula (III) are conveniently symmetric. In general, compounds of formula (III) in which W represents CO, CS or SO will be used. Thus, for example, especially useful compounds include N,N'-carbonyldi( 1 2,4-triazole), N,N'-carbonyldibenzotriazole, N,N'-carbonyldibenzimidazole, N,N'-carbonyldi(3 5-dimethylpyrazole), N,N'-thionyldiimidazole and especially N,N'-carbonyldiimidazole and N,N'-thiocarbonyldiimidazole.
The preparation of a 1 7a-hydroxy 1 7P-carbothioic acid having the formula (II) as herein defined is conveniently effected by reaction of a 17a-hydroxy 1 7P-carboxylic acid with a compound of formula (III) followed by reaction of the intermediate product having the 17p-COR7 grouping with hydrogen sulphide or a salt thereof preferably in situ without isolation of the intermediate.
The 17&alpha;-acyloxy 17ss-carbothioic acid of formufa II may be obtained in a similar manner directly form the corresponding 17&alpha;-acyloxy 17ss-carboxylic acid by reaction with a compound of formula (III) The 1 7a-acyloxy 17p-carboxylic acids may be prepared by esterification of the corresponding 1 7a- acyloxy 17p-carboxylic acids by the methods described in BP 1 384,372.
The reaction with the compound of formula (III) is conveniently effected in the presence of an inert anhydrous solvent e.g. a substituted amide solvent such as N,N-dimethylformamide or N,Ndimethylacetamide, desirably in the absence of water, advantageously at or below ambient temperature, e.g. at a temperature of from -300C to +300C. The reaction is conveniently effected under approximately neutral conditions, advantageously in an inert atmosphere, e.g. under nitrogen. The same solvents and conditions are also applicable to the subsequent reaction with H2S or a salt thereof.
The heterocyclic compound e.g. imidazole or 1,2,4-triazole formed as a by-product may, for example, be readily removed by extraction with water.
The foregoing reactions may also be carried out on compounds having a variety of substituents or groupings which are subsequently converted as described previously to compounds of formula (I).
The androstane 17p-carboxylic acid starting materials employed in the above processes may be prepared in conventional manner, e.g. by oxidation of an appropriate 21 -hydroxy-2O-keto pregnane for example with periodic acid, in a solvent medium and preferably at room temperature. Alternatively, sodium bismuthate may be employed to effect the desired oxidative removal of the 21-carbon atom of a 17P-acyloxy pregnane compound. As will be appreciated should the starting pregnane compound contain any substituent sensitive to the above desired oxidation, such a group should be suitably protected.
The following examples illustrate the invention.
Melting points were determined in C on a Kofler block and are uncorrected. Optical rotations were determined at room temperature on solutions in dioxan.
T.l.c. (Thin layer chromatography), p.l.c. (Preparative layer chromatography) and h.p.l.c. (High performance liquid chromatography) were carried out over silica.
Solutions were dried over magnesium sulphate unless stated otherwise.
PREPARATION 1 9&alpha;-Fluoro-11ss-hydroxy-16ss-methyl-3-oxo-17&alpha;-propionyloxyandrosta-1,4-diene-17ss-carbothioic acid (I) A solution fo 9&alpha;-fluoro-11ss-hydroxy-16ss-methyl-3-oxo-17&alpha;-propionyloxyandrosta-1.4-diene- 17ss-carboxylic acid (5.00 g) solvated with ethyl acetate (1/2 mole) and triethylamine (5.3 ml) in dichloromethane (75 ml) was stirred under nitrogen and treated with dimethyithiocarbamoyl chloride (5.071 g). After 24 h more reagent (5.320 g) was added. After 47 h the mixture was diluted with ethyl acetate and washed with N-hydrochloric acid, 5% sodium bicarbonate solution and water, dried and evaporated to give a viscous yellow oil (9.043 g). This was dissolved in diethylamine (50 ml) then stirred and heated at reflux under nitrogen for 5.75 h.The resulting brown solution was added to a mixture of concentrated hydrochloric acid (50 ml), water (250 ml) and ethyl acetate (50 ml). The products were further extracted with ethyl acetate, then the acid products were back-extracted into 5% sodium carbonate solution. The aqueous phase was acidified with 6N-hydrochloric acid (50 ml) and extracted with ethyl acetate. The extracts were washed with N-hydrochloric acid and water, dried and evaporated to a buff solid (3.440 g). This was recrystallised from acetone to give pale buff crystals (1.980 g) of the title 17p-carbothioic acid, m.p. 172-173 .
The analytical sample was obtained after two recrystallizations from acetone as white crystals, m.p. 177-179 , [&alpha;]D+110 (c 1.05).
PREPARATION II S-Chloromethyl 9&alpha;-fluoro-16ss-methyl-3,11-dioxo-17&alpha;-propionuyloxyandrosta-1,4-diene-17ss- carbothioate (II) 8N-Jones reagent (1.5 ml) was added dropwise over 10 mins to a stirred solution of the compound of Example 1 (hereinafter disclosed) (998 mg) in acetone (2 ml) and dimethylformamide (2 ml). After 30 mins the reaction mixture was slowly diluted with water (100 ml) with stirring, and the resulting suspension was refrigerated for 1 h. The precipitate was collected by filtration, washed with water and dried to give a cream coloured solid (877 mg). P.l.c. in chloroform-acetone (10:1) gave a white foam (755 mg) which was crystallised twice from acetone to give white needles of the title 11ketone (523 mg) m.p. 204-205 , [&alpha;]D +940 (c 1.04).
PREPARATION III 17ss N,N Dimethylthiocarbamoyloxycarbonyi-9 a-fluoro-l 1 -hydroxy- 1 6a-methyl- 17 a- propionyloxyandroxta-1,4-diene-3-one (III) A solution of 9a-fluoro-11 ss-hydroxy-16&alpha;-methyl-3-oxo-17&alpha;-propionyloxyandrosta-1,4-diene- 17ss-carboxylic acid (0.434 g) in dichloromethane (8 ml) was treated successively with triethylamine (0.14 ml), dimethylthiocarbamoyl chloride (0.248 g), and sodium iodide (0.149 g) and the mixture was stirred under nitrogen at 200C for 6 h. Ethyl acetate (30 ml) was added and the total volume was reduced by half in vacuo. Further ethyl acetate (50 ml) was added and the solution was washed with water, 2N-hydrochloric acid, water, 3% sodium hydrogen carbonate, water and saturated sodium chloride solution then dried.The solution was concentrated in vacuo when the product crystallised (0.329 g). This was recrystallised from acetone (2x) to give the title anhydride as white needles, m.p.
191-193 , [&alpha;]D +82 (c0.57).
PREPARATION IV 9&alpha;-Fluoro-11ss-hydroxy-16&alpha;-methyl-3-oxo-17&alpha;-propionyloxyandrosta-1,4-diene-17ss-carbothioic acid (IV) A stirred suspension of (III) (2.467 g) in diethylamine (25 ml) was heated at reflux under nitrogen.
After 3.5 h. the reaction was poured into iced 3N hydrochloric acid (300 ml) and the mixture was extracted with ethyl acetate. The combined extracts were washed with water and were extracted with 5% sodium carbonate solution. The combined aqueous extracts were washed with ethyl acetate, then covered with ethyl acetate and acidified with hydrochloric acid to pH 1. The aqueous phase was extracted with further ethyl acetate and the combined extracts were washed with water, saturated sodium chloride solution, dried and the solvent was removed in vacuo. The residue was crystallised twice from acetone to give the title carbothioic acid as white needles (1.309 g) m.p. 141-143 , , +30 (c 0.51).
PREPARATION V 11ss-Hydroxy-3-oxo-17&alpha;-propionyloxyandrosta-1,4-diene-17ss-carboxylic acid (V) A solution of 11ss,17&alpha;-dihydroxy-3-oxoandrosta-1,4-diene 17ss-carboxylic acid (13.5 g), and triethylamine (18 ml) in dichloromethane (500 ml) was cooled to 40C and treated portionwise during 15 minutes with propionyl chloride (14.2 ml). Stirring was continued at 40C for a total time of 1 h and the mixture was washed successively with 3% sodium hydrogen carbonate, water, 2N-hydrochloric acid, water and saturated brine, then dried and evaporated under reduced pressure. The residue was dissolved in acetone (300 ml) and diethylamine (14.3 ml) was added with stirring. After 1 h at 200C the solvent was removed under reduced pressure, and the residue was dissolved in water (150 ml).After acidification to pH 1 with 2N-hydrochloric acid the product was extracted with ethyl acetate. The combined extracts were washed with water and saturated brine, dried and then concentrated to a low volume. The solid product was collected by filtration, washed with ethyl acetate and dried in vacuo at 500 to give the title 1 7a-propionate carboxylic acid as crystals (1 3.309 g), []D +2 (c 1.10). A portion (389 mg) was recrystallised twice from methanol to give an analytical sample (256 mg) m.p.
244245 (decomp), [ar], +30 (c 0.83).
PREPARATION VI 6a,9a-Difluoro- 11 p-hydroxy- 16zz-methyl-3-oxo- 17a-propionyloxyandrosta- 1,4-diene-l 7P-carboxylic acid (VI) A solution of 6a,9a-difluoro-1 1ss, 17&alpha;-dihydroxy-16&alpha;-methyl-3-oxoandrosta-1,4-diene-17ss- carboxylic acid (2.113 g) and triethylamine (2.5 ml) in dichloromethane (60 ml) was stirred and treated at ca 0 C with propionyl chloride (1.85 ml). After 1 h the mixture was diluted with more solvent (50 ml) and washed successively with 3% sodium hydrogen carbonate, water, 2N-hydrochloric acid, water, saturated brine, then dried and evaporated to a buff solid. This was dissolved in acetone (50 ml) and diethylamine (2.5 ml) was added. After 1 h at 220C the solvent was removed in vacuo and the residual gum was dissolved in water (30 ml).Acidification to pH 1 with 2N-hydrochloric acid precipitated a solid, which was collected, washed with water, and dried to give the title carboxylic acid 1 7a-propionate (2.230 g), m.p. 220-225 , [aS]D +40 (c 0.70).
PREPARATION VII 17ss-N,N-Dimethylthiocarbamoyloxycarbonyl-9&alpha;-fluoro-11ss-hydroxy-16&alpha;,17&alpha;- isopropylidenedioxyandrosta- 1 ,4-diene-3-one (VII) A solution of 9&alpha;-fluoro-11ss-hydroxy-16&alpha;, 17&alpha;-isopropylidenedioxy-3-oxoandrosta-1,4-diene- 17ss-crboxylic acid (1.000 g) in dichloromethane (15 ml) and triethylamine (0.33 ml) under nitrogen was treated with N,N-dimethylthiocarbamoyl chloride (588 mg) and the mixture was stirred at room temperature. After 68 h the reaction mixture was diluted with ethyl acetate (50 ml) and washed with N hydrochloric acid (2.10 ml), 5% sodium hydrogen carbonate solution and water, dried and evaporated to a pale yellow crystalline solid (1.123 g).P.l.c. of a portion (200 mg) in chloroform-acetone (9:1) gave an off-white solid (161 mg) which crystallised from ethyl acetate as white needles of the title mixed anhydride (131 mg), m.p. 279-281 , [&alpha;]D+174 (c 0.61, dimethyisulphoxide).
PREPARATION VIII 17ss-N,N-Dimethylthiocarbamoyloxycarbonyl-6&alpha;,9&alpha;-difluoro-11ss-hydroxy-16&alpha;, 17&alpha; isopropylidenedioxyandrosta-1,4-diene-3-one (VIII) A solution of 6&alpha;,9&alpha;-difluoro-11ss-hydroxy-16&alpha;, 17&alpha;-isopropylidenedioxy-3-oxoandrosta-1,4- diene-17ss-carboxylic acid (4.354 g) in dichloromethane (150 ml) containing triethylamine (1.4 ml), was treated with N,N-dimethylthiocarbamoyl chloride (2.519 g) and the reaction was stirred under nitrogen at 220 for 80 min. Ethyl acetate (500 ml) was added and the resulting solution was successively washed with 2N-hydrochloric acid, water, sodium hydrogen carbonate solution, water and saturated sodium chloride solution and dried and the solution was concentrated.On cooling, crystallisation occurred and the solid was filtered and dried in vacuo to give the title anhydride (3.562 g) as pale yellow prisms, m.p. 283-287 (dec), [a] +1560 (c 0.84, dimethylsulphoxide).
PREPARATION IX 6&alpha;,9&alpha;-Difluoro-11ss-hydroxy-16&alpha;, 17&alpha;-isopropylidenedioxy-3-oxoandrosta-1,4-diene-17ss-carbothioic acid (IX) A suspension of VIII (3.455 g) in diethylamine (200 ml) was heated under reflux under nitrogen for 6 h. The initial suspension quickly dissolved, but a pale brown suspension formed after 30 min and remained unchanged. The cooled reaction mixture was poured into water (1.01), acidified with concentrated hydrochloric acid (210 ml) to pH 1 and extracted with ethyl acetate. The combined extracts were washed with water, and extracted with 5% sodium carbonate solution and water and the aqueous extracts were combined. The combined extracts were acidified with 6N-hydrochloric acid and extracted with ethyl acetate.The combined organic extracts were washed with water and saturated sodium chloride solution, then dried, and the solvent was removed in vacuo to give a pale grey solid (2.31 g). Part of the product (0.408 g) was crystallised from ethyl acetate to give the title carbothioic acid (0.149 g), m.p. 191-199 , [al + 1240 (c 1.04, dimethylsulphoxide).
PREPARATION X 6&alpha;-Fluoro-11ss, 17&alpha;-dihydroxy-3-oxoandrosta-1,4-diene-17ss-carboxylic acid (X) A solution of 6a-fluoroprednisolone (4.987 g) in tetrahydrofuran (50 ml) was stirred with a solution of periodic acid (10.0 g) in water (24 ml) at 220. After 50 mins the tetrahydrofuran was evaporated and the aqueous suspension was filtered. The solid product was washed with water (300 ml) and dried to give a white solid (4.80 g). A portion (271 mg) was crystallised from methanol to give the title acid(1 71 mg) as white needles, m.p. 241-248 , [Cg]D +540 (c 0.825).
PREPARATION Xl 6&alpha;-Fluoro-11ss-hydroxy-3-oxo-17&alpha;-propionyloxyandroxat-1,4-diene-17ss-carboxylic acid (XI) A solution of X (4.491 g) and triethyiamine (4.46 ml) in dry dichloromethane (160 ml) at-5 was stirred and treated dropwise with propionyl chloride (2.80 ml., 2.96 g) in dry dichloromethane (ca. 5 ml.) during 5 min at below 00. After a further 20 min below 0 the reaction mixture was diluted with dichloromethane (160 ml), washed with sodium hydrogen carbonate solution, water, dried and evaporated to a white solid (5.701 g). This was stirred with diethylamine (4.60 ml, 3.24 g) in acetone (30 ml) to give a clear yellow solution. After 30 minutes the solution was concentrated, water was added (150 ml) and the resulting solution was washed with ethyl acetate (2 x 30 ml).The aqueous phase was acidified to pH 2 using 2N-hydrochloric acid (50 ml) with stirring and the product extracted with ethyl acetate three times. The extracts were combined, washed with water (50 ml), dried and evaporated to give a white foam (5.819 g). A portion of the foam (304 mg) was crystallised from ethyl acetate to give the title 1 7a-propionate (144 mg) as small plates, m.p. 224-227 , [a], +30 (c 0.861).
PREPARATIONS Xll-XXlll Following the same general procedure as described in Preparation I but using as starting material the 17ss-carboxylic acid corresponding to the desired 17ss-carbothioate (process details being summarised in Table 1 below), the following compounds were prepared: XII. 17&alpha;-Acetoxy-9&alpha;-fluoro-11ss-hydroxy-16ss-methyl-3-oxoandrosta-1,4-diene-17ss-carbothioic acid, m.p. 178.5-179 , [a], +980 (c 1.02).
XIII. 1 7a-Butyryloxy-9a-fluoro-1 1 P-hydroxy-l GP-methyl-3-oxoandrosta-l ,4-diene-l 7P- carbothioic acid, m.p. 175-176 , [a!]D + 1070 (c 0.96).
XIV. 9&alpha;-Fluoro-11ss-hydroxy-17&alpha;-isobutyryloxy-16ss-methyl-3-oxoandrosta-1,4-diene-17ss- carbothioic acid, m.p. 177-179, [&alpha;]C + 119 (c 0.90).
XV. 11ss-Hydroxy-3-oxo-17&alpha;-propionyloxyandrosta-1,4-diene-17ss-carbothioic acid, m.p.
134-138 , [&alpha;]D +67 (c 0.66).
XVI. 11ss-Hydroxy-16ss-methyl-3-oxo-17&alpha;-propionyloxyandrosta-1,4-diene-17ss-carbothionic acid, m.p. 159-163 , [&alpha;]D +113 (c 0.78).
XVII. 9&alpha;-Chloro-11ss-hydrox-16ss-methyl-3-oxo-17&alpha;-propionyloxyandrosta-1,4-diene-17ss- carbothioic acid, m.p. 167-171, [&alpha;]D + 128 (c 0.99).
XVIII. 9&alpha;-Fluoro-11ss-hydroxy-16&alpha;-methyl-3-oxo-17&alpha;-propionyloxyandrosta-1,4-diene-17ss- carbothioic acid, m.p. 141-143 , [c]o +300 (c 0.51).
XIX. 6&alpha;,9&alpha;-Difluoro-11ss-hydroxy-16&alpha;-methyl-3-oxo-17&alpha;-propionyloxyandrosta-1,4-diene-17ss- carbothioic acid, m.p. 136-139 , [&alpha;]D-30 (c 0.56).
XX. 9&alpha;-Fluoro-11ss-hydroxy-16-methylene-3-oxo-17&alpha;-propionyloxyandrosta-1,4-diene-17ss- carbothioic acid, m.p. 236-139 , [&alpha;]D-71 (c 0.99).
XXI. 11ss-Hydroxy-3-oxo-17&alpha;-propionyloxyandrosta-4-ene-17ss-carbothioic acid, m.p.
176-177 , [&alpha;]D + 101 (c 0.96).
XXII. 9&alpha;-Fluoro-1 11,B-hydroxy- 16a,17cr-isopropylidenedioxy-3-oxoandrosta- ,4-diene-1 17p- carbothioic acid, m.p. 274-304 (dec.), [&alpha;]D + 121 0 (c 0.51, dimethylsulphoxide).
XXIII. 6&alpha;-Fluoro-11ss-hydroxy-3-oxo-17&alpha;-propionyloxyandrosta-1,4-diene-17ss-carbothioic acid, m.p. 189-193 . [&alpha;]D +72 (c 0.74).
TABLE I Formation of the mixed an hydrides
17ss- Reaction carboxylic Solvent Time (days) acid Input Cl-CSNMe2 NEt3 (CH2Cl2) at room Preparation (g) (g) (ml) (ml) temperature XII 5.000 2.940 1.66 75 51a XIII 15.354 8.809 4.8 250 6 XIV 4.182 2.399 1.3 80 4 XV 7.148 4.40 2.6 150 61b XVI 6.137 3.77 2.05 140 61c XVII 5.973 3.350 1.34 100 7 XVII I 4.207 2.39 1.35 80 0.677 ld XIX 2.130 1.80 0.66 50 XX 5.000 2.507 1.41 75 3 XXI 1.000 2.442 1.22 15 2.7 XXII 1.000 0.588 0.33 15 2.88 XXIII 6.000 3.55 2.0 120 1.2510 TABLE I (Continued) Treatment of the mixed anhydride intermediates with diethylamine
Reaction NHEt2 Time (h) Product Crystallisation Preparation (ml) at reflux (g) Solvent L xii 50 5.5 2.104 EA2a XIII 250 4 5.244 EA3 XIV 60 4.5 1.00 EA XV 60 4 3.29 EA XVI 50 3.5 1.382 EA XVII 60 5.7 0.527 EA XVIII 25 4.75 1.309 A XIX 12 6 0.418 EA XX 50 3.75 1.296 EA2b XXI 15 4 0.3976 A5 XXII (a) 8 (a) 3 0.4649 A (b) 16 (b) 2.5 XXIII 60 4.5 2.88 EA-P Notes: EA = ethyl acetate. A = acetate. P = petrol b.p. 60--800 1. Portions (a) 500 mg, (b) 670 mg, (c) 424 mg, (d) 171 mg. of the intermediate dimethylthiocarbamic anhydride were removed for characterisation.
2. Characterisation was carried out on a sample recrystaliised twice more from ethyl acetate.
Recoveries (a) 84% (b) 69%.
3- Product was solvated with ethyl acetate (ca 0.2 mol).
4. The intermediate dimethylthiocarbamic anhydride (1.435 g) crystallised from ethyl acetate. A portion (95 mg) was removed for characterisation.
5. Characterisation was carried out on a sample recrystallised twice more from acetone (recovery: 73%).
6. Product crystallised from ethyl acetate.
7. Sodium iodide (1.46 g) was also present in the reaction.
8- The intermediate dimethylthiocarbamic anhydride (1.123 g) crystallised from ethyl acetate. A portion (200 mg) was chromatographed (p.l.c., chloroform-acetone, 9:1) and recrystallised from ethyl acetate (recovery 65%).
9 Reaction carried out on 781 mg of anhydride.
10. Sodium iodide (2.13 g) was also present in the reaction.
PREPARATION XXIV 9&alpha;-Chloro-11ss-hydroxy-16ss-methyl-3-oxo-17&alpha;-propionyloxyandrosta-1,4-diene-17ss-carbothioic acid and 9ss,11ss-epoxy-16ss-methyl-3-oxo-17&alpha;-propionyloxyandrosta-1,4-diene-17ss-carbothioic acid (XXIV) A solution of 17ss-N,N-dimethylthiocarbamoyloxycarbonyl-9&alpha;-chloro-11 P-hydroxy-l 6P-m ethyl- 1 7a-propionyloxyandrosta-1 ,4-diene-3-one (5.586 g.) in diethylamine (60 ml) was refluxed under nitrogen for 5 h 40 min. The reaction was poured into water (450 ml), acidified to pH 10 with concentrated hydrochloric acid and extracted with ethyl acetate (3 x 60 ml). The combined extracts were washed with water then extracted with aqueous sodium carbonate solution (4 x 50 ml).The aqueous extracts were acidified with 6N-hydrochloric acid to pH 1 and extracted with ethyl acetate (3 x 50 ml). The combined extracts were washed with water and saturated sodium chloride solution and dried and the solvent removed in vacuo to give a colourless froth (2.834 g).
Two crystallisations of the mixture from ethyl acetate gave 9a-chloro- 11 ss-hydroxy-16ss-methyl- 3-oxo- 1 7&alpha;-propionyloxyandrosta- 1,4-diene- 1 7ss-carbothioic acid (0.527 g) as white prisms, m.p. 167 to 171 0, [aC]D + 1280 (c 0.99). The mother liquors from the crystallisations contained an additional quantity of the above 9a-chloro-1 1 ,1-hydroxycarbothioic acid together with 9ss,11ss-epoxy-1 6,B-methyl- 3-oxo- 1 7&alpha;-proplonyloxyandrosta- 1,4-diene- 1 7,B-carbothioic acid.
PREPARATION XXV S-lodomethyl 9&alpha;-fluoro-11ss-hydroxy-16ss-methyl-3-oxo-17&alpha;-proplonyloxyandrosta-1,4-diene-17ss- carbothioate (XXV) A solution of the compound of Example 1 (hereinafter disclosed) (500 mg) and sodium iodide (1.874 g) in acetone (15 ml) was stirred and heated under reflux for 6.5 h. Ethyl acetate (75 ml) was then added and the solution was washed successively with water, 10% sodium thiosulphate solution, 5% sodium hydrogen carbonate solution and water, dried and evaporated to give an off-white foam (525 mg). P.l.c. in chloroform-acetone (6:1) gave an off-white foam (478 mg) which was crystallised twice from acetone without being heated above room temperature to give colourless crystals of the title S-iodomethyl ester (241 mg) m.p. 196-197 , [&alpha;]D-32 (c 1.01).
PREPARATIONS XXVI-XXXVII Following the same general procedure as described in Preparation XXV but using as starting material the S-chloromethyl 1 7,1-carbothioate corresponding to the desired product (process details being summarised in Table II below), the following compounds were prepared: XXVI. S-lodomethyl 17&alpha;-acetoxy-9&alpha;-fluoro-11ss-hydroxy-16ss-methyl-3-oxoandrosta-1,4-diene- 17ss-carbothloate, m.p. 204-205 , [&alpha;]D-29 (c 0.98).
XXVII. S-lodomethyl 11ss-hydroxy-3-oxo-17&alpha;-propionyloxyandrosta-1,4-diene-17ss-carbothioate, [a]0 +260 (c 0.47).
XXVIII. S-lodomethyl 11ss-hydroxy-16ss-methyl-3-oxo-17&alpha;-proplonyloxyandrosta-1,4-diene-17ss- carbothioate, [&alpha;]D +50 (c 0.74).
XXIX. S-lodomethyl 9&alpha;-chloro-11ss-hydroxy-16ss-methyl-3-oxo-17ss-proplonyloxyandrosta-1,4- diene-17ss-carbothloate, [a]D +70 (c 0.36).
XXX. S-lodomethyl 9&alpha;-fluoro-11ss-hydroxy-16&alpha;methyl-3-oxo-17&alpha;-propionyloxyandrosta-1,4- diene-17ss-carbothioate, [&alpha;]D+85 (c 0.55).
XXXI. S-lodomethyl 6 a,9 a-difluoro-1 1 ss-hydroxy-16&alpha;-methyl-3-oxo-17&alpha;-propionyloxyandrosta-1,4- 1,4-diene-17ss-carbothioate.
XXXII. S-lodomethyl 9&alpha;-fluoro-11ss-hydroxy-16-methylene-3-oxo-17&alpha;-propionyloxyandrosta- 1,4-diene-17ss-carbothioate, m.p. 191-199 , [&alpha;]D-31 (c 0.99).
XXXIII. S-lodomethyl 9&alpha;-fluoro-11ss-hydroxy-3-oxo-17&alpha;-propionyloxyandrosta-1,4-diene-17ss- carbothioate, m.p. 175-178 , [&alpha;]D +4 (c 0.50).
XXXIV. S-lodomethyl 6&alpha;-fluoro-11ss-hydroxy-3-oxo-17&alpha;-propionyloxyandrosta-1,4-diene-17ss- carbothioate, m.p. 1951970, [a!]D +180 (c 0.64).
XXXV. S-lodomethyl 17 a-acetoxy-6a,9 a-difluoro- 11 ss-hydroxy-16&alpha;-methyl-3-oxoandrosta-1,4- diene-17ss-carbothloate, m.p. 241-243 , [&alpha;]D + 78 (c 0.78).
XXXVI. S-lodomethyl 17&alpha;-butyryloxy-6&alpha;,9&alpha;-difluoro-11ss-hydroxy-16&alpha;-methyl-3-oxoandrosta- 1,4-diene-17ss-carbothioate, m.p. 210-212 , [&alpha;]D +89 (c 0.90).
XXXVII. S-lodomethyl 9&alpha;-fluoro-11ss-hydroxy-16&alpha;,17&alpha;-isopropylidenedioxy-3-oxoandrosta-1,4- diene-17,1-carbothioate, m.p. 261-270 (dec.), [a]o +970 (c 0.48, dimethylsulphoxide).
TABLE II Halogen Exchanges on S-haloalkyl 1 7a-acyloxyandrostane-1 7Bcarbothioates
STARTING STEROID REACTION PLC SOLVENT TIME (h) (Silica) CRYSTAL Prepara- Nal HALIDE INPUT (acetone) (at CHCl3- LISATION PRODUCT tion No. (mg) (mg) (ml) reflux) Me2CO SOLVENT (mg) XXVI 6632 Cl 1715 20 3.5 - EA 2161 XXVII 3800 Cl 925 10 4 ~ ~ 1084 XXXVII i 3260 Cl 840 10 3 ~ ~ 969 XXIX 1995 Cl 536 20 6.5 ~ ~ 591 XXX 2160 Cl 580 10 3 ~ ~ 685 XXXI 1200 Cl 303 30 5 ~ - 3173 XXXII 7361 Cl 1953 23 6 19::1 A 2962 XXXIII 5500 Cl 1300 35 4 ~ M 12507 XXXIV 8400 Cl 2000 54 4.5 - . FA-P 1800 XXXV 19000 CI 4750 200 5 ~ EA 46206 XXXVI 6500 Cl 1620 70 5.5 ~ EA 16105 XXXVII 5491 Cl 1419 20 24 9:1 A 2246 EA = ethyl acetate A = acetone M = methanol P = petrol b.p. 60-80 Notes 1. Obtained from a portion (300 mg) of the crude product (2.024 g).
2. Obtained from a portion (400 mg) of the crude product (2.058 g).
3- The product was used directly for the preparation of the corresponding fluoromethyl 1 7,1- carbothioate.
4- Lithium chloride was used in place of sodium iodide.
5. Solvated with 0.5 H20.
6. Solvated with 0.1 EA.
7- Solvated with 0.2 EA + 0.5 H20.
8. Obtained from a portion (300 mg) of the crude crystalline product (1.611 9).
PREPARATION XXXVIII S-lodomethyl 6&alpha;,9&alpha;-difluoro-11ss-hydroxy-16&alpha;,17&alpha;-isopropylidenedioxy-3-oxoandrosta-1,4-diene- 17ss-carbothioate (XXXVIII) A solution of the compound of Example 4 hereinafter disclosed (0.795 g) in acetone (50 ml) was heated under reflux with sodium iodide (2.969 g) for 5.5 h. Ethyl acetate (75 ml) was added and the solution was washed successively with water, sodium metabisulphite solution, then dried and the solvent removed in vacuo to give an off-white solid (0.893 g). Part (0.205 g) of this was crystallised twice from ethyl acetate to give the title S-iodomethylthioester (0.105 g) as white prisms, m.p.
260-262 (dec.), [a], +810 (c 0.6, dimethylsulphoxide).
PREPARATION XXXIX S-2'-Bromoethyl 9&alpha;-fluoro-11ss-hydroxy-17ss-methyl-3-oxo-17&alpha;-propionyloxyandrosta-1,4-diene-17ss- carbothioate (XXXIX) 1(0.5 g) was treated as described for the S-chloromethyl ester (Example 1 Method A hereinafter disclosed) but using 1,2-dibromoethane to give colourless crystals of the title S-2'-bromoethyl ester (0.409 9), m.p. 174-145 , [&alpha;]D + 1200 (c 1.04).
PREPARATION XL 16&alpha;,17&alpha;-Epoxy-9&alpha;-fluoro-11ss-hydroxy-16&alpha;-methyl-3-oxoandrosta-1,4-diene-17ss-carbothioic acid (XL) A mixture of 1 6a,1 7a-epoxy-9a-fluoro-1 1,1-hydroxy-1 6,1-methyl-3-oxoandrosta-1 ,4-diene-1 7,1- carboxylic acid (377 mg) and 2-fluoro-1 -methylpyridinium tosylate (340 mg) in dry dichloromethane (7 ml) was stirred, cooled in ice, and treated during 1 min with triethylamine (0.42 ml). After 1 h, hydrogen sulphide was passed through the mixture for 30 min to give a yellow solution. T.l.c.
(chloroform-acetone-acetic acid, 30:8:1) showed a major less polar product had formed. After being allowed to warm to room temperature during 1 h the mixture was treated with 2N-hydrochloric acid (30 ml), and the product was extracted with ethyl acetate (3 x 20 ml). The acidic product was extracted from the organic phase with 5% sodium carbonate, the aqueous extracts were combined and acidified with 6N-hydrochloric acid, then extracted with ethyl acetate. The combined acidic extracts were washed with water, dried and concentrated under reduced pressure to give, after filtration, off-white crystals (274 mg) probably largely the unstable 1 6a,1 7a-epoxy-9a4luoro-1 1 ,1-hydroxy-1 6,1-methyl-3- oxoandrosta-1,4-diene-17ss-carbothioic acid (no starting oxyacid present) as judged by t.l.c.
(chloroform-acetone-acetic acid 30:8:1, Fr ca 0.7).
PREPARATION XLI S-Chloromethyl 16&alpha;,17&alpha;-epoxy-9&alpha;-fluoro-11ss-hydroxy-16ss-methyl-3-oxoandrosta-1,4-diene-17ss- carbothioate (XLI) Method A A suspension of 16&alpha;, 17&alpha;-epoxy-9&alpha;-fluoro-11ss-hydroxy-16ss-methyl-3-oxoandrosta-1,4-diene- 17ss-carboxylic acid (753 mg) and 2-fluoro-1-methylpyridinium tosylate (680 mg) in dichloromethane (7 ml) was treated dropwise at 0 C with triethylamine (1.39 ml), and then stirred at 0 C for 1 h.
Hydrogen sulphide was then passed through the mixture for 15 min and then the resulting solution was stirred at 0 C for a further 1 h. Bromochloromethane (0.26 ml) was then added and the mixture was stirred and allowed to warm to room temperature. After a further 1.5 h the reaction mixture was diluted with ethyl acetate (250 ml) and washed successively with 2N-hydrochloric acid, 5% sodium hydrogen carbonate solution and water, dried and evaporated to a pale yellow solid (818 mg). The solid was subjected to p.l.c. in chloroform-acetone (9:1) (two runs). The major band (515 mg) was crystallised from acetone to give white needles of the title S-chloromethyl ester epoxide (447 mg), m.p.
246-251 , [Cg]D +1310 (c 0.67).
Method B A suspension of 1 6a, 1 7a-epoxy-9a4luoro-1 1 ss-hydroxy-16-methylene-3-oxoandrosta-1,4- diene-17ss-carboxylic acid (376 mg) and 2-chloro-N-methylbenzothiazolium trifluoromethane sulphonate (400 mg) in dichloromethane was treated dropwise at 0 C with triethylamine (0.7 ml). The resulting solution was stirred at 0 C for 1.25 h and then hydrogen sulphide was passed through the mixture for 10 min. After a further 1 h at 0 C bromochloromethane (0.13 ml) was added and the mixture was stirred at room temperature. Two more portions of bromochloromethane (0.13 ml) were then added after a further 1.5 h and 1.8 h.Fifteen min. after the final addition the reaction mixture was diluted with ethyl acetate (200 ml) and washed successively with 2N-hydrochloric acid, 5% sodium hydrogen carbonate solution and water, dried and evaporated to a red crystalline solid. The solid was subjected to p.l.c. in chloroform-acetone (19:1) (three runs). The more polar band gave a pale pink solid, the title S-chloromethyl ester (134 mg), identical to an authentic sample on t.l.c.
PREPARATION XLII S-Chloromethyl 9&alpha;-fluoro-11ss, 17&alpha;-dihydroxy-16-methylene-3-oxoandrosta-1,4-diene-17ss- carbothioate (XLII) A solution of XLI (400 m-4) in trifluoroacetic acid (16 ml) was stirred at room temperature. After 5.5 h the reaction mixture was evaporated to near dryness and the residue dissolved in ethyl acetate (100 ml). The solution was washed with 5% sodium hydrogen carbonate solution and water, dried and evaporated to a yellowish-green foam (466 mg). The foam was subjected to p.l.c. in chloroform-acetone (9:1) (three runs).A portion (80 mg) of the major band (315 mg) was crystallised twice from acetone to give white crystals of the title 16-methylene 17&alpha;-alcohol(48 mg), m.p. 242-243 , []D +360 (c 0.50).
.PREPARATION XLIII 9&alpha;-Fluoro-17&alpha;-hydroxy-16ss-methyl-3,11-dioxoandrosta-1,4-diene-17ss-carboxylic acid (XLIII) A stirred suspension of 9&alpha;-fluoro 17.21-dihydroxy-16ss-methylandrosta-1,4-diene-3,11,20-trione (4.842 g) in tetrahydrofuran (50 ml) was cooled in ice and treated dropwise over 5 min with a solution of periodic acid (4.255 g) in water (1 5 ml). The reaction was stirred at 220 for 2.25 h, when most of the suspension had dissolved. The solvent was removed in vacuo, with periodic addition of water to maintain the original volume. The resulting precipitate was filtered off, washed with water and dried in air and in vacuo to give the title carboxylic acid as cream prisms (4.55 g) mp 270272 (dec), [&alpha;]D + 1360 (c 1.04, dimethylsulphoxide).
PREPARATION XLIV 9a-Fluorn-1 1,1,1 7a-dihydroxy-1 6,1-methyl-3-oxoandrosta-1 ,4-diene-1 7,1-carbothioic acid (XLIV) A stirred solution of 9a-fluoro-1 1ss,17&alpha;-dihydroxy-16ss-methyl-3-oxoandrosta-1,4-diene-17ss- carboxylic acid (0.502 g) in dry N,N-dimethylformamide (15 ml) was cooled at -50 under nitrogen and treated with N,N'-carbonyldiimidazole (0.435 g) and the reaction was stirred at-5 for 18 h. Hydrogen sulphide gas was bubbled into the reaction for 20 min and the solution was stirred for a further 4 h, gradually being allowed to warm to 220. The reaction was poured into ethyl acetate and the resulting solution was washed with 2N-hydrochloric acid and water, then extracted with 2N-sodium carbonate solution (3 x 50 ml).The combined extracts were washed with ethyl acetate (60 ml) then covered with further ethyl acetate (100 ml) and acidified with hydrochloric acid to pH 1.0. The aqueous layer was extracted with further ethyl acetate and the extracts were washed with water and saturated sodium chloride solution, then dried and the solvent was removed in vacuo to give a white solid which was crystallised twice from ethyl acetate to give the title carbothioic acid (0.315 g) m.p. 198-201 0 (dec), [a]0 +1890 (c0.71).
PREPARATION XLV 9&alpha;-Fluoro-17&alpha;-hydroxy-16ss-methyl-3,11-dioxoandrosta-1,4-diene-17ss-carbothioic acid (XLV) A stirred solution of XLIII (5.587 g) in dry N,N-dimethylformamide (150 ml) at 200 under nitrogen was treated with N,N'-carbonyldiimidazole (4.847 g) and the reaction was stirred at 200 for 4 h.
Hydrogen sulphide gas was bubbled into the reaction for 10 min and the solution was stirred for a further hour. The solution was poured onto ice (300 ml) and 2N-hydrochloric acid (100 ml) to give a buff precipitate. This was filtered off, air-dried overnight (6.268 g) and crystallised from ethyl acetate to give the title carbothioic acid (3.761 g) as white prisms, m.p. 2152180, [a]D +1430 (c 0.88, dimethylformamide).
PREPARATION XLVI 9&alpha;-Fluoro-17&alpha;-hydroxy-16ss-methyl-3,11 -dioxoandrosta-1 ,4-diene-1 7,1-carbothioic acid (XLVI) A stirred solution of XLIII (1.059 g) in dry N,N-dimethylformamide (50 ml) at 200 under nitrogen was treated with N,N'-thiocarbonyldiimidazole (1.368 g) and the reaction was stirred at 200 for 4 h.
Hydrogen sulphide gas was bubbled into the reaction for 5 min and the solution was stirred for a further hour. The reaction was partitioned between ethyl acetate (100 ml) and 2N-hydrochloric acid (100 ml) and the organic phase was washed with 2N-hydrochloric acid (100 ml) and water (2 x 100 ml) and was extracted with 2N-sodium carbonate solution (2 x 75 ml). The combined extracts were washed with ethyl acetate (50 ml), then covered with ethyl acetate (100 ml) and acidified with hydrochloric acid to pH 1. The aqueous layer was extracted with further ethyl acetate (50 ml) and the combined extracts were washed with water, saturated sodium chloride solution, dried, and the solvent was removed in vacuo. The residue was crystallised from ethyl acetate to give the title carbothioic acid (0.559) m.p.
212-219 , [a]0 + 1450 (c 0.81, dimethylformamide).
PREPARATION XLVII S-Chloromethyl 9a-fluoro-1 1,1,1 7a-dihydroxy-1 16p-methyl-3-oxoandrosta- 1 ,4-diene-1 7,1-carbothioate (XLVII) A stirred solution of XLIV (0.169 g) and sodium hydrogen carbonate (0.040 g) in N,Ndimethylformamide (6 ml) was treated with bromochloromethane (0.1 ml) and stirring was continued at 220 for 1 h. The reaction mixture was diluted with ethyl acetate (100 ml) and the solution was successively washed with 2N-hydrochloric acid, water, 2N-sodium carbonate solution, water and saturated sodium chloride solution, then dried and the solvent was removed in vacuo. The residue was crystallised twice from ethyl acetate to give the title S-chloromethylthiolester (0.193 g) as white plates solvated with ethyl acetate (1 mol), m.p. 126-130, [(g]D + 147.5 (c 0.64).
PREPARATION XLVIII 9a-Fluoro-1 6,1-methyl-3, 11 -dioxo-17&alpha;-propionyloxyandrosta-1,4-diene-17ss-carbothioic acid (XLVlil).
A stirred solution of XLV (0.485 g) and triethylamine (0.57 ml) in dichloromethane was cooled in ice-salt, treated with propionyl chloride (0.43 ml) and the reaction was stirred at 0 for 1.5 h. The mixture was partitioned between ethyl acetate (75 ml) and 2N-sodium carbonate solution (75 ml) and the organic layer was successively used with further 2N-sodium carbonate solution, water, 2Nhydrochloric acid, water, and saturated sodium chloride solution, then dried and the solvent removed in vacuo to give a yellow crystalline solid (0.562 g). This was dissolved in acetone (10 ml), diethylamine (1.0 ml) was added and the reaction was stirred at 220 for 1.25 h. The solvents were removed In vacuo and the residue was partitioned between ethyl acetate (30 ml) and 2N-hydrochloric acid (30 ml).The ethyl acetate layer was washed with water and extracted with 2N-sodium carbonate solution (2 x 30 ml). The combined extracts were washed with ethyl acetate (30 ml) and covered with ethyl acetate (60 ml) and acidified to pH 1.0 with hydrochloric acid. The ethyl acetate layer was washed with water and saturated sodium chloride solution, then dried and the solvent was removed in vacuo to give a white solid which was crystallised twice from ethyl acetate to give the title ester (0.290 g), m.p. 173-1 800, [CE]D +1480 (c 1.03).
PREPARATION XLIX S-Chloromethyl 9&alpha;-fluoro-17&alpha;-hydroxy-16ss-methyl-3,11-dioxoandrosta-1,4-diene-17ss-carbothioate (XLIX) A solution of XLV (5.006 g), and sodium bicarbonate (1.612 g) in N,N-dimethylacetamide (50 ml) was treated with bromochloromethane (1.24 ml) and the reaction was stirred at 220 for 3.3 h. The solution was diluted with ethyl acetate (70 ml) and washed successively with 2N-hydrochloric acid, water, sodium metabisulphite solution, water and saturated sodium chloride solution, then dried and the solvent was removed in vacuo to give a cream solid (3.638 g).The analytical sample was obtained after preparative t.l.c. (silica gel, developed with chloroform:acetone = 9.1), and crystallised from ethyl acetate as colourless prisms of the title ester (0.262 g), m.p. 223-228 , [&alpha;]D +2510 (c 1.2).
PREPARATION L 9cz-Fluoro-11 ss-hydroxy-16ss-methyl-3-oxo-17&alpha;-propionyloxyandrosta- 1,4-diene- 17p-carbothioic acid (L) A stirred solution of XLIV (0.511 g) in dichloromethane (20 ml) containing triethylamine (0.6 ml) was cooled to 20 and treated with propionyl chloride (0.45 ml) and the reaction was stirred at 20 for 2.5 h. The reaction was partitioned between ethyl acetate and sodium hydrogen carbonate and the organic phase was washed with water, 2N-hydrochloric acid, water and saturated sodium chloride solution, dried and the solvent removed in vacuo to give a colourless solid (0.634 g). This was dissolved in acetone (30 ml), at 220 for 55 min. The reaction was diluted with ethyl acetate (50 ml) and was washed with 2N-hydrochloric acid and water then extracted with 5% sodium carbonate solution.The combined extracts were acidified with 2N-hydrochloric acid to pH 1 and extracted with ethyl acetate.
The combined extracts were washed with water and saturated sodium chloride solution and dried and the solvent removed to give a colourless froth (0.522 g) which was crystallised from ethyl acetate to give the title ester as colourless prisms (0.307 g) m.p. 174-179 , [aS]D +1070 (c 1.0).
PREPARATION LI 9&alpha;-Fluoro-11ss, 17&alpha;-dihydroxy-16-methylene-3-oxoandrosta-1,4-diene-17ss-carbothioic acid (LI) A solution of 9&alpha;-fluoro-11ss, 17&alpha;-dihydroxy-16-methylene-3-oxoandrosta-1,4-diene-17ss- carboxylic acid (0.218 g) in dry N,N-dimethylformamide (10 ml) at 22" under nitrogen was treated with N,N'-carbonyldiimidazole (0.254 g) and the reaction was stirred at 220 for 4 h. Hydrogen sulphide gas was bubbled into the reaction for 5 min and the mixture, now pale green, was stirred for 1 h at 220.The mixture was diluted with ethyl acetate (150 ml) and the solution was washed with 2N-hydrochloric acid, water and saturated sodium chloride solution, dried and the solvent removed in vacuo to give a yellow froth (0.222 g) which was crystallised twice from ethyl acetate to give the title carbothioic acid (0.078 g) as white prisms, decomposed at ca. 2500 without melting, [aS]D +1170 (c 0.32).
PREPARATION LII 9&alpha;-Fluoro-11ss, 17&alpha;-dihdyroxy-3-oxoandrosta-1,4-diene-17ss-carboxylic acid (LII) A suspension of 9cg-fluoroprednisolone (10 g) in dry tetrahydrofuran (55 ml) was stirred and treated with a solution of periodic acid (9.0 g) in water (90 ml) and the mixture was stirred at 220 for 2 h. It was then poured into iced-water (ca. 400 ml) and, after being stirred for 15 min., the solid product was collected, washed with water, and dried to give the title acid as a solid (9.42 g). A portion recrystallised from ethanol had m.p. 289-293 [aC]D +660 (c 0.73, methanol).
PREPARATION Llil 9a-Fluoro-1 1ss,17&alpha;-dihydroxy-3-oxoandrosta-1,4-diene-17ss-carbothioic acid (LIII) A solution of 9&alpha;-fluoro-11ss,17&alpha;-dihydroxy-3-oxoandrosta-1,4-diene-17ss-carboxylic acid (4.5 g) in dry dimethylformamide (100 ml) was stirred under nitrogen with N,N'-carbonyldiimidazole (4.04 g) at 220C for 4 h. Hydrogen sulphide was then passed through the solution for 30 min and then kept for a further 15 min. The mixture was poured into a mixture of 2N-hydrochloric acid (250 ml) and ice (ca 100 g) and the resulting precipitate was collected, washed with water and dried to give a white solid (4.56 g).A portion (120 mg) was recrystallised from ethanol to give the title thioacid as colourless crystals (70 mg), m.p. 222-225 , [a], +1160 (c 0.57).
PREPARATION LIV 6a,9a-Difluoro-1 1ss,17&alpha;-dihydroxy-16&alpha;-methyl-3-oxoandrosta-1,4-diene-17ss-carbothioic acid (LIV) A solution of 6a,9a-difluoro- 11 ss,17&alpha;-dihydroxy-16&alpha;-methyl-3-oxoandrosta- 1 ,4-diene- 17,1- carboxylic acid (12.0 g) in dry dimethylformamide (250 ml) was stirred and treated with N,N'carbonyldiimidazole (9.94 g) under nitrogen at room temperature. After 4 h, hydrogen sulphide was passed through the solution for 0.5 h and the mixture was kept for a further 0.5 h. The reaction mixture was poured into 2N-hydrochloric acid (500 ml) containing ice (ca 250 g). The resulting precipitate was collected, washed with water and dried in vacuo to give the title thioacidas a white solid (11.47 g), m.p.
230-232 , [a], +940 (c0.91).
PREPARATION LV 17&alpha;-Acetoxy-6&alpha;,9&alpha;-difluoro-11ss-hydroxy-16&alpha;-methyl-3-oxoandrosta-1,4-diene-17ss-carbothioic-acid (LV) A solution of LIV (1.625 g) and triethylamine (2.0 ml) in dichloromethane (75 ml) was stirred at ca OOC, treated dropwise with acetyl chloride (1.275 ml), then stirred at this temperature for 1.25 h. The mixture was washed with 2N-sodium carbonate (50 ml), water, 2N-hydrochloric acid (50 ml), water (3 x 50 ml), brine (50 ml), then dried and evaporated to a white solid (1.91 g). This was dissolved in acetone (40 ml) and stirred with diethylamine (4 mi) at 270C for 45 min.The mixture was concentrated to ca 25 ml and poured into 2N-hydrochloric acid (100 ml) containing ice (ca 100 g): after being stirred the resulting precipitate was collected, washed with water and dried to give a solid (1.685 g). A portion (400 mg) was recrystallised from ethyl acetate to give the title 1 7a-acetate (280 mg), m.p.
1751770.
PREPARATION LVI 17&alpha;-Butyryloxy-6&alpha;,9&alpha;-difluoro-11ss-hydroxy-16&alpha;-methyl-3-oxoandrosta-1,4-diene-17ss-carbothioic acid (LVI) Using a similar procedure to that described in Preparation LV, LIV (2.0 g) was converted, with butyryl chloride (1.5 ml) instead of acetyl chloride, to the title 1 7(x-butyrate (2.08 g). a portion recrystallised from ethyl acetate had m.p. 155-157 .
PREPARATION LVII 9a-Fluoro- 11 ,1-hydroxy-3-oxo-1 17cr-propionyloxyandrosta- ,4-diene-1 7,1-carbothioic acid (LVI I) Using a similar procedure to that described in Preparation LV, LIII (3.8 g) was converted, using propionyl chloride (3.9 ml) instead of acetyl chloride and after aminolysis of the intermediate with diethylamine (10.35 ml), into the title 1 7a-propionate (4.17 g). A portion (350 mg) recrystallised from ethyl acetate gave colourless crystals (-1 65 mg), m.p. 135-138 , [a]0 +720 (c 0.92).
PREPARATION LVI II 6&alpha;,9&alpha;-Difluoro-11ss-hydroxy-16&alpha;-methyl-3-oxo-17&alpha;-propionyloxyandrosta-1,4-diene-17ss-carbothioic acid (LVII I) A solution of LIV (5.0 g) and triethylamine (6.15 ml) in dichloromethane (140 ml) was cooled with ice-salt and treated dropwise with propionyl chloride (4.74 ml). The reaction mixture was stirred further at ca 0 C for 0.75 h then washed successively with 2N-sodium carbonate, water, 2N-hydrochloric acid, water and brine. After being dried, solvent was removed to give a white solid (6.35 g). This was redissolved in acetone (120 ml) and diethylamine (12.5 ml): after being stirred at room temperature for 1 h the volume was reduced to ca 75 ml.The solution was poured into 2N-hydrochloric acid (200 ml) containing ice (ca 300 g) and the resulting precipitate was collected, washed with water and dried in vacuo to a white solid (5.17 g) m.p. 152-155 . Recrystallisation of a portion (400 mg) from ethyl acetate gave the analytically pure title thioacid 1 7a-propionate as colourless crystals (290 mg), m.p.
161-164 , [a]0 -27" (c 0.95), whose solid-state infrared spectrum (in Nujol) showed a different crystalline form from the sample obtained in Preparation XIX.
PREPARATION LIX S-Chloromethyl 9&alpha;-fluoro-16ss-methyl-3,11-dioxo-17&alpha;-propionyloxyandrosta-1,4-diene-17ss- carbothioate (LIX) A solution of XLIX (409 mg) in propionic acid (5 ml), trifluoroacetic anhydride (2 ml) and toluene p-sulphonic acid (0.1 ml of dry chloroform solution, 80 mg/ml) was stirred at 22 OC for 2.75 days. The non-acidic product was isolated by extraction with ethyl acetate after being poured into saturated sodium hydrogen carbonate. The crude material was chromatographed on silica in chloroform-acetone (14:1) and crystallised from ethyl acetate-petrol (b.p. 60-800C) to give the title 17a-propionate as colourless crystals, m.p. 205-206", []D +95 (c 1.15).
PREPARATION LX S-Chloromethyl 9&alpha;-fluoro-11ss,17&alpha;-dihydroxy-16ss-methyl-3-oxoandrosta-1,4-diene-17ss-carbothioate (LX) A suspension of XLIX (102 mg) in ethanol (2.5 ml) was stirred with sodium borohydride (10 mg) at 220C for 1 h. The reaction mixture was treated with acetone (5 ml) then concentrated to near dryness: the residue was dissolved in ethyl acetate (25 ml), washed with N-hydrochloric acid, water, and brine.
After being dried the organic solvent was removed to give the title 1 1 p-alcohol as a colourles foam (103 mg) whose sole major component was equipolar with an authentic specimen on t.l.c. comparison (silica, chloroform-acetone, 9:1).
PREPARATION LXI 9&alpha;-Fluoro-11ss-hydroxy-16ss-methyl-3-oxo-17&alpha;-propionyloxyandrosta-1,4-diene-17ss-carbothioic acid (LXI) Method A A solution of 9-fluoro- 11 p-hydroxy- 6,1-methyl-3-oxo-1 7a-propionyloxyandrosta-1 4-diene- 17je-carboxylic acid (603 mg, 0.75 mol ethyl acetate solvate) and N,N'-carbonyldi(1 2,4-triazole) (0.997 mg) in dry dimethylformamide (45 ml) was stirred under nitrogen at ca 22 C for 18.5 h. A solution (15 ml) prepared from sodium hydride (305 mg) in dimethylformamide by saturating with hydrogen sulphide, was added and stirring was continued at ambient temperature for 3 days.The reaction mixture was poured into 2N-hydrochloric acid (200 ml) and the product was extracted with ethyl acetate (3x). The organic extracts were combined, washed with water and back extracted with 5% sodium carbonate solution: the alkaline extracts were acidified with hydrochloric acid and extracted with ethyl acetate (3 x). After being washed with water and brine the organic extracts were dried and concentrated to low volume: the title thioacidseparated as cream crystals (101 mg), whose sole major component was identified by comparison with an authentic specimen by 1H nmr and by t.l.c. (silica, chloroform-acetone 4:1).
Method B A solution of 9 a-fl uoro- 11 ,1-hydroxy- 1 6,1-methyl-3-oxo-1 711-propionyloxyandrosta- 1 ,4-diene- 1 7,1-carboxylic acid (701 mg, 0.75 mol ethyl acetate solvate) and N,N'-carbonyldiimidazole (473 mg) in dry dimethylformamide (26 mg) was stirred under nitrogen at ca 22 C for 1 9.5 h., then treated with a solution (10 ml) of sodium hydride (60% dispersion in oil, 233 mg) in dimethylformamide (10 ml) saturated with hydrogen sulphide. The resulting mixture was then stirred at ambient temperature for 5.5 h. The reaction mixture was diluted with ethyl acetate (100 ml) and washed with 2N-hydrochloric acid, water and brine, then dried and evaporated to a froth (186 mg).The title thioacid was shown to be the major component in the product by 1H nmr and by t.l.c. (silica, chloroform-acetone [4:1], and chloroform-acetone-acetic acid [30:8:1]) comparison with an authentic specimen.
Method C In an almost identical reaction to that described in Method A the carboxylic acid was treated with 1,1'-carbonyldibenzotriazole (1.587 g) instead of N,N'-carbonyidi(1,2,4-triazole), at room temperature for 6 h. After the addition of the solution obtained from hydrogen sulphide and sodium hydride in dimethylformamide, reaction was continued for 41.5 h. The crude product was obtained as a foam; t.l.c.
(silica, chloroform-acetone, 4:1; and chloroform-acetone-acetic acid 30:8:1) showed the title thioacid was present as a major component by comparison with an authentic specimen.
PREPARATION LXII S-Chloromethyl 6a,9a-difluorn- 1 6a-methyl-3-oxo- 1 7a-propionyloxy-1 1 ,1-trifluoroacetoxyandrosta- 1,4-diene-l 7P-carbothioate (LXI I) A solution of the compound of Example 5 (hereinafter disclosed) (100 mg) in dry tetrahydrofuran (2 ml) and pyridine (0.1 ml) was treated with trifluoroacetic anhydride (0.05 ml) and the mixture was kept at room temperature for 0.5 h. The reaction mixture was poured into water and the product was extracted with ethyl acetate (3x). The organic extracts were washed with water, dried and evaporated to give the homogeneous title trifluoroacetate (116 mg) according to 1H nmr spectroscopy (singlet at 8.S9T, 1 9-protons, in deuterio-chloroform) and t.l.c. on silica (acetone-petrol, b.p. 40-60"C, 1:3). An analytical sample from ether-pentane had m.p. 158-162", [aC]D +56" (c 0.23).

Claims (33)

CLAIMS 1. Compounds of the general formula (Il) (wherein Ra represents a thiocarbamoyloxycarbonyl group COOCSNRARB where RA and RB are as defined above or a group of the formula COSRIA, where R1A represents a hydrogen atom or is a group as defined below for R' or is a group convertible thereto and Rb represents an esterified hydroxyl group or Rb and RC together represent an isopropylidenedioxy group; or where Ra represents a group COSR'A, Rb is optionally a hydroxyl group; Rc represents a hydrogen atom, a methyl group (which may be in either the a- or ,B-configuration) or a methylene group; Rd represents a hydroxy or protected hydroxy group (in either the a- or ,1-configuration) or an oxo group; Re represents a hydrogen, bromine, chlorine or fluorine atom; or Rd and Re together represent a carbon-carbon bond or an epoxy group in the ss-configuration; Rf represents a hydrogen or a fluorine atom; and the symbol ---- represents a single or double bond and salts of those compounds which have a free carbothioic acid group; with the exclusion of compounds of the formula: wherein R1 represents a fluoro-, chloro- or bromo-methyl group or a 2'-fluoroethyl group, R2 represents a group COR6 where R6 is a C1-3 alkyl group or OR2 and R3 together form a 16&alpha;, 17&alpha;- isopropylidenedioxy group; R3 represents a hydrogen atom, a methyl group (which may be in either the a- or p-configuration) or a methylene group; R4 represents a hydrogen, chlorine or fluorine atom; R5 represents a hydrogen or fluorine atom and the symbol ---- represents a single or double bond. 2. Compounds as claimed in claim 1 in which Ra represents-COSH, Rb represents a hydroxyl group, Rc represents a hydrogen atom, an &alpha;- or ss-methyl group or a methylene group, Re represents a hydrogen, chlorine or fluorine atom, and Rd represents a hydroxl group in the ss-configuration or an oxo group. 3. A process for the preparation of compounds as claimed in claim 1 carrying a free -COSH group in the 17ss-position wherein (a) a compound as claimed in claim 1 carrying a thiocarbamoyloxycarbonyl group in the 17,B- position is subjected to aminolysis with rearrangement; (b) a compound corresponding to formula II as claimed in claim 1 carrying a 16&alpha;, 17&alpha;-epoxy or 16&alpha;, 17&alpha;-isopropylidenedioxy group but having a 17ss-carboxy group or a salt thereofis reacted with a 2-haio-aza-aromatic compound followed by hydrogen sulphide;; (c) a compound corresponding to formula II as claimed in claim 1 in which Rb is a hydroxy group but carrying at the 1 7,1-position a group in which X, Y and Z, which may be the same or different each represent CH or N, is reacted with hydrogen sulphide or a sulphide or hydrosulphide salt thereof. Amendments to the claims have been filed, and have the following effect: (a) Claims 1-3 above have been deleted or textually amended. (b) New or textually amended claims have been filed as follows: CLAIMS
1. Compounds of the general formula (II)
[wherein Ra represents a thiocarbamoyloxycarbonyl group-COOCSNRARB (where RA and RB, which may be the same or different, are alkyl groups or RA and RB together with the nitrogen atom to which they are attached form a 5-8 membered ring which may optionally contain an additional hetero atom selected from oxygen, nitrogen and sulphur and/or which may be optionally substituted by one or two C13 alkyl groups) or a group of the formula-COSR1A (where RIA represents a hydrogen atom or is a group as defined below for R1 or is the group (CH2)nY in which n is 1 or 2 and Y represents a displaceable substituent) and Rb represents an esterified hydroxyl group or Rb and RC together represent an isopropylidenedioxy group; or where Ra represents a group COSR'A, Rb is optionally a hydroxyl group; RC represents a hydrogen atom, a methyl group (which may be in either the a- or p-configuration) or a methylene group; Rd represents a hydroxy or protected hydroxy group (in either the a- or p-configuration) or an oxo group; Re represents a hydrogen, bromine, chlorine or fluorine atom; or Rd and Re together represent a carbon-carbon bond or an epoxy group in the p-configuration; Rf represents a hydrogen or a fluorine atom; and the symbol # represents a single or double bond] and salts of those compounds which have a free carbothioic acid group; with the exclusion of compounds of the formula:
wherein R1 represents a fluoro-, chloro- or bromo-methyl group or a 2'-fluoroethyl group, R2 represents a group COR6 where R6 is a C13 alkyl group or OR2 and R3 together form a 1 6a,1 7a- isopropylidenedioxy group; R3 represents a hydrogen atom, a methyl group (which may be in either the a- or ,1-configuration) or a methylene group; R4 represents a hydrogen, chlorine or fluorine atom; R5 represents a hydrogen or fluorine atom and the symbol ---- represents a single or double bond.
2. Compounds as claimed in claim 1 wherein Ra represents-COSH and Rb represents a hydroxy group.
3. Compounds as claimed in claim 1 wherein R'A represents a chloromethyl orfluoromethyl group.
4. Compounds as claimed in claim 1 wherein Rb represents an acetoxy or propionyloxy group.
5. Compounds as claimed in claim 4 wherein Rb represents a propionyloxy group.
6. Compounds as claimed in any one of the preceding claims wherein Re represents a fluorine atom.
7. Compounds as claimed in any one of the preceding claims wherein Rf represents a fluorine atom.
8. Compounds as claimed in any one of the preceding claims which are 1 4-dienes.
9. Compounds as claimed in claim 8 wherein Re represents a fluorine atom and RC represents a hydrogen atom, or an a- or methyl or methylene group.
10. Compounds as claimed in claim 8 wherein RIA represents a chloro- or fluoro-methyl group and Re and Rf each represents a fluorine atom.
11. Compounds as claimed in claim 10 wherein RC represents an methyl group.
12. Compounds as claimed in any one of claims 1 to 5, 7 and 8 wherein Rd and Re together represent an epoxy group.
13. Compounds as claimed in claim 1 in which Ra represents -COSH, Rb represents a hydroxyl group, Rc represents a hydrogen atom, an a- or methyl group or a methylene group, Re represents a hydrogen, chlorine or fluorine atom, and Rd represents a hydroxyl group in the ,1-configuration or an oxo group.
14. Compounds as claimed in claim 2 wherein RC represents a methyl group in the a- or ,1- configuration or a methylene group; Re represents a fluorine atom, Rd represents a hydroxy group in the ,1-configuration or an oxo group and the symbol ---- in the 1,2-position represents a carbon-carbon double bond.
15.9&alpha;-Fluoro-11ss, 17&alpha;-dihydroxy-16ss-methyl-3-oxoandrosta-1,4-diene-17ss-carbothioic acid and the salts thereof.
16.9&alpha;-Fluoro-17&alpha;-hydroxy-16ss-methyl-3,11-dioxoandrosta-1,4-diene-17ss-carbothioic acid and the salts thereof.
17.9&alpha;-Fluoro-11ss,17&alpha;-dihydroxy-16&alpha;-methyl-3-oxoandrosta-1,4-diene-17ss-carbothioic acid and the salts thereof.
18.9&alpha;-Fluoro-17&alpha;-hydroxy-16&alpha;-methyl-3,11-dioxoandrosta-1,4-diene-17ss-carbothioic acid and the salts thereof.
19.9&alpha;-Fluoro-11ss,17&alpha;-dihydroxy-16-methylene-3-oxoandrosta-1,4-diene-17ss-carbothioic acid and the salts thereof.
20.9&alpha;-Fluoro-17&alpha;-hydroxy-16-methylene-3,11-dioxoandrosta-1,4-diene-17ss-carbothioic acid and the salts thereof.
21.6&alpha;-Difluoro-11ss,17&alpha;-dihydroxy-16&alpha;-methyl-3-oxoandrosta-1,4-diene-17ss-carbothioic acid and the salts thereof.
22.6&alpha;,9&alpha;-difluoro-17&alpha;-hydroxy-16&alpha;-methyl-3,11-dioxoandrosta-1,4-diene-17ss-carbothioic acid and the salts thereof.
23. A process for the preparation of compounds as claimed in claim 1 carrying a free -COSH group in the 17p-position wherein a compound as claimed in claim 1 carrying a thiocarbamoyloxycarbonyl group in the 1 7,1-position is subjected to aminolysis with rearrangement.
24. A process for the preparation of compounds as claimed in claim 1 carrying a 1 6-methylene group and a free -COSH group in the 17p-position wherein a compound corresponding to formula II as claimed in claim 1 carrying a 1 6,1-methyl and a 1 6a,1 7a-epoxy group but having a 1 7,1-carboxyl group or a salt thereof is reacted with an onium salt of a 2-haloaza-aromatic compound followed by hydrogen sulphide and the 16ss-methyl-16&alpha;,17&alpha;,-epoxy 1 7,1-thiocarboxylic acid product thus obtained is subjected to rearrangement with a strong acid followed, if desired, by esterification of the 17&alpha;- hydroxy group.
25. A process for the preparation of compounds as claimed in claim 1 carrying a 1 6a,1 7a- isopropylidenedioxy group and a free -COSH group in the 1 7,1-position wherein a compound corresponding to formula II as claimed in claim 1 carrying a 1 6a,1 7a-isopropylidenedioxy group but having a 17ss-carboxyl group or a salt thereof is reacted with an onium salt of a 2-haloazo-aromatic compound followed by hydrogen sulphide.
26. A process for the preparation of compounds as claimed in claim 1 carrying a free -COSH group in the 17p-position wherein a compound corresponding to formula II as claimed in claim 1 in which Rb is a hydroxy group but carrying at the 17ss-position a groupCOR7 in which R7 represents the group
(in which X, Y and Z, which may be the same or different each represent CH or N, one or two of X, Y and Z being N, the heterocyclic ring optionally being substituted on at least one carbon atom by a C14 alkyl group and/or where the heterocyclic ring contains two adjacent carbon atoms, the said ring optionally carrying a benzene ring fused to the said adjacent carbon atoms) is reacted with hydrogen sulphide or a sulphide or hydrosulphide salt thereof.
27. A process as claimed in claim 26 wherein the said compound corresponding to formula II but carrying the group-COR7 at the 17ss-position is first prepared by reaction of a compound corresponding to formula II but carrying a carboxylic acid group at the 17p-position with a symmetric or asymmetric compound of the formula: F7-W-F7 lil wherein W represents the group CO, CS; SO or SO2 and the groups R7, which may be the same or different, are as defined in claim 26.
28. A process according to claim 27 wherein a compound of formula Ill is used in which W represents the group CO, CS or SO.
29. A process according to claim 28 wherein the compound of formula Ill used is N,N'carbonyldi(1,2,4-triazole), N,N'-carbonyldibenzotriazole, N,N'-carbonyldibenzimidazole, N,N'carbonyldi(3,5-dimethylpyrazole), N,N'-thiocarbonyldiimidazole or N,N'-thionyldiimidazole.
30. A process according to claim 28 wherein the compound of formula Ill used is N,N'carbonyldiimidazole.
31. A process according to claim 27 wherein reaction of a compound corresponding to a compound of formula II, but carrying a 17ss-carboxylic acid group with a compound of formula Ill is followed in situ by reaction of the compound corresponding to formula II, but carrying the group-COR7 at the 1 7ss-position, thus obtained, with hydrogen sulphide or a sulphide or hydrosulphide salt without isolation of the compound corresponding to formula II, but carrying the groupCOR7 at the 17p- position.
32. A process for the preparation of a compound of formula II wherein Rb represents a hydroxy group and Ra represents the group-COSR1 in which R1 is as defined in claim 1 which comprises esterifying a compound of formula II in which Rb represents a hydroxy group and Ra represents the group-COSH.
33. A process for the preparation of a compound of formula II wherein Ra represents the group -COSH and Rb represents an esterified hydroxyl group which comprises esterifying a compound of formula II in which Rb represents a hydroxy group and Ra represents the group -COSH.
GB08325400A 1980-02-15 1983-09-22 Androstane 17-carbothioc acid derivatives Expired GB2137206B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB08325400A GB2137206B (en) 1980-02-15 1983-09-22 Androstane 17-carbothioc acid derivatives

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB8005174 1980-02-15
GB8013339 1980-04-23
GB08325400A GB2137206B (en) 1980-02-15 1983-09-22 Androstane 17-carbothioc acid derivatives

Publications (3)

Publication Number Publication Date
GB8325400D0 GB8325400D0 (en) 1983-10-26
GB2137206A true GB2137206A (en) 1984-10-03
GB2137206B GB2137206B (en) 1985-04-03

Family

ID=27260865

Family Applications (1)

Application Number Title Priority Date Filing Date
GB08325400A Expired GB2137206B (en) 1980-02-15 1983-09-22 Androstane 17-carbothioc acid derivatives

Country Status (1)

Country Link
GB (1) GB2137206B (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994013690A1 (en) * 1992-12-11 1994-06-23 Rhone-Poulenc Rorer Limited New steroids
WO1994014834A1 (en) * 1992-12-24 1994-07-07 Rhone-Poulenc Rorer Limited New steroids
WO2005005451A1 (en) 2003-07-11 2005-01-20 Glaxo Group Limited Specific glucocorticosteroid compound having anti- inflammatory activity
WO2006043015A1 (en) 2004-10-19 2006-04-27 Hovione Inter Ltd. Process for the esterification of a carbothioic acid
US7214807B2 (en) 2000-02-25 2007-05-08 Abbott Laboratories Method for the preparation of fluticasone and related 17β-carbothioic esters using a novel carbothioic acid synthesis and novel purification methods
US7579335B2 (en) 2005-01-10 2009-08-25 Glaxo Group Limited Androstane 17α-carbonate derivatives for use in the treatment of allergic and inflammatory conditions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0004741A2 (en) * 1978-04-05 1979-10-17 Syntex (U.S.A.) Inc. Thio etianic acid derivatives, their preparation and pharmaceutical use
GB2079755A (en) * 1980-07-10 1982-01-27 Otsuka Pharma Co Ltd Androstene 17 alpha -carbonate 17 beta -carboxylates (and carbothioates)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0004741A2 (en) * 1978-04-05 1979-10-17 Syntex (U.S.A.) Inc. Thio etianic acid derivatives, their preparation and pharmaceutical use
GB2079755A (en) * 1980-07-10 1982-01-27 Otsuka Pharma Co Ltd Androstene 17 alpha -carbonate 17 beta -carboxylates (and carbothioates)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994013690A1 (en) * 1992-12-11 1994-06-23 Rhone-Poulenc Rorer Limited New steroids
WO1994014834A1 (en) * 1992-12-24 1994-07-07 Rhone-Poulenc Rorer Limited New steroids
US5801165A (en) * 1992-12-24 1998-09-01 Rhone-Poulenc Rorer Limited Antiinflammatory, immunosuppressive and antialleric 16, 17-alkylidioxy-steroids
US7214807B2 (en) 2000-02-25 2007-05-08 Abbott Laboratories Method for the preparation of fluticasone and related 17β-carbothioic esters using a novel carbothioic acid synthesis and novel purification methods
US7288536B2 (en) 2003-07-11 2007-10-30 Glaxo Group Limited Specific glucocorticosteroid compound having anti-inflammatory activity
WO2005005451A1 (en) 2003-07-11 2005-01-20 Glaxo Group Limited Specific glucocorticosteroid compound having anti- inflammatory activity
US7291609B2 (en) 2003-07-11 2007-11-06 Glaxo Group Limited Specific glucocorticosteroid compound having anti-inflammatory activity
US7524970B2 (en) 2003-07-11 2009-04-28 Glaxo Group Limited Compounds
AU2004255854B2 (en) * 2003-07-11 2009-10-22 Glaxo Group Limited Specific glucocorticosteroid compound having anti- inflammatory activity
US7638508B2 (en) 2003-07-11 2009-12-29 Glaxo Group Limited Glucocorticosteroid compound having anti-inflammatory activity
WO2006043015A1 (en) 2004-10-19 2006-04-27 Hovione Inter Ltd. Process for the esterification of a carbothioic acid
US9670246B2 (en) 2004-10-19 2017-06-06 Hovione Inter Ltd. Process for the esterification of a carbothioic acid
US7579335B2 (en) 2005-01-10 2009-08-25 Glaxo Group Limited Androstane 17α-carbonate derivatives for use in the treatment of allergic and inflammatory conditions

Also Published As

Publication number Publication date
GB2137206B (en) 1985-04-03
GB8325400D0 (en) 1983-10-26

Similar Documents

Publication Publication Date Title
US4335121A (en) Androstane carbothioates
GB2088877A (en) Androstane 17 beta carbothioates
US4377575A (en) Corticoid-17-(alkyl carbonates) and process for their manufacture
CA1118411A (en) Corticoid 17-(alkyl carbonates) and processes for their preparation
DK147735B (en) ANALOGY PROCEDURE FOR PREPARING 3-OXO-ANDROST-4-EN-17BETA-THIOCARBOXYL ACID ESTERS
US4650610A (en) Androstane carbothioic acids
GB2137206A (en) Androstane 17-carbothioc acid derivatives
Takeda et al. A Partial Synthesis of Caranine1
JP3037508B2 (en) Novel substituted 16-methyl steroid derivatives of pregna-1,4-diene-3,20-dione, their preparation, their use in the preparation of 16-methylene steroids and novel intermediates
CA1205464A (en) Androstane carbothioates
US3741997A (en) Process for the preparation of pregnane derivatives
CA2473471A1 (en) Method for the preparation of 6-alpha-fluoro corticosteroids
IE51395B1 (en) Steroids of the androstane series
IE51394B1 (en) Androstane carbothioates
EP0053845B1 (en) 17-beta-ethynylsteroids and process for preparing same
EP0136586B1 (en) Novel corticoid derivatives and process for production thereof
US4207235A (en) Selective epoxidation of steroidal bromohydrins
US4602009A (en) Corticoid derivatives and process for production thereof
US3767685A (en) Novel 11beta-halo-steroids of the oestrane series
US3325483A (en) Introducing unsaturation into steroid compounds
JPS5826359B2 (en) gonatrienka gobutsunoseizouhou
US4519949A (en) Steroid-20-carboxylic acid compounds and a process for their production
US4049804A (en) Novel pregnanoic acid derivatives
US4585766A (en) 6-oxygenated corticoid 17α-carbonates and process for production thereof
KR810000582B1 (en) Process for the preparation of corticoid 17-(alkyl catbonates)

Legal Events

Date Code Title Description
PE20 Patent expired after termination of 20 years

Effective date: 20010212